Association between osteocalcin, metabolic syndrome, and cardiovascular risk factors: Role of total and undercarboxylated osteocalcin in patients with type 2 diabetes

International Journal of Endocrinology

Volumn 2013, Issue , 2013, Pages

  Alfadda, Assim A ^a   Masood, Afshan ^a   Shaik, Shaffi Ahamed ^a   Dekhil, Hafedh ^a   Goran, Michael ^b  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OSTEOCALCIN; TRIACYLGLYCEROL;

ADULT; AGE; ARTICLE; BODY MASS; CARBOXYLATION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 84877306332     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2013/197519     Document Type: Article

References (24)

1. Tan A., Gao Y., Yang X., Zhang H., Qin X., Mo L., Peng T., Xia N., Mo Z., Low serum osteocalcin level is a potential marker for metabolic syndrome: results from a Chinese male population survey. Metabolism 2011 60 8 1186 1192 2-s2.0-79960554187 10.1016/j.metabol.2011.01.002
2. Saleem U., Mosley T. H. Jr., Kullo I. J., Serum osteocalcin is associated with measures of insulin resistance, adipokine levels, and the presence of metabolic syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology 2010 30 7 1474 1478 2-s2.0-77953921007 10.1161/ATVBAHA.110.204859
3. Gomez-Ambrosi J., Rodriguez A., Catalan V., The bone-adipose axis in obesity and weight loss. Obesity Surgery 2008 18 9 1134 1143
4. Lee A. J., Hodges S., Eastell R., Measurement of osteocalcin. Annals of Clinical Biochemistry 2000 37 432 446 (Pubitemid 30426723)
5. Lee N. K., Sowa H., Hinoi E., Endocrine regulation of energy metabolism by the skeleton. Cell 2007 130 3 456 469 (Pubitemid 47208519)
6. Ferron M., Hinoi E., Karsenty G., Ducy P., Osteocalcin differentially regulates β cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proceedings of the National Academy of Sciences of the United States of America 2008 105 13 5266 5270 2-s2.0-42449096306 10.1073/pnas.0711119105 (Pubitemid 351738545)
7. Benayahu D., Shamay A., Wientroub S., Osteocalcin (BGP), gene expression, and protein production by marrow stromal adipocytes. Biochemical and Biophysical Research Communications 1997 231 2 442 446 2-s2.0-0031566254 10.1006/bbrc.1997.6116 (Pubitemid 27214330)
8. Thiede M. A., Smock S. L., Petersen D. N., Grasser W. A., Thompson D. D., Nishimoto S. K., Presence of messenger ribonucleic acid encoding osteocalcin, a marker of bone turnover, in bone marrow megakaryocytes and peripheral blood platelets. Endocrinology 1994 135 3 929 937 2-s2.0-0027964253 10.1210/en.135.3.929 (Pubitemid 24271181)
9. Kim S. H., Lee J. W., Im J. A., Hwang H. J., Serum osteocalcin is related to abdominal obesity in Korean obese and overweight men. Clinica Chimica Acta 2010 411 23-24 2054 2057 2-s2.0-77957750707 10.1016/j.cca.2010.08.046
10. Kindblom J. M., Ohlsson C., Ljunggren O., Karlsson M. K., Tivesten Å., Smith U., Mellström D., Plasma osteocalcin is inversely related to fat mass and plasma glucose in elderly Swedish men. Journal of Bone and Mineral Research 2009 24 5 785 791 2-s2.0-65949124446 10.1359/jbmr.081234
11. Shea M. K., Gundberg C. M., Meigs J. B., Dallal G. E., Saltzman E., Yoshida M., Jacques P. F., Booth S. L., γ -carboxylation of osteocalcin and insulin resistance in older men and women. American Journal of Clinical Nutrition 2009 90 5 1230 1235 2-s2.0-70350650807 10.3945/ajcn.2009.28151
12. Kanazawa I., Yamaguchi T., Yamauchi M., Yamamoto M., Kurioka S., Yano S., Sugimoto T., Serum undercarboxylated osteocalcin was inversely associated with plasma glucose level and fat mass in type 2 diabetes mellitus. Osteoporosis International 2011 22 1 187 194 2-s2.0-78651518046 10.1007/s00198-010-1184-7
13. Iki M., Tamaki J., Fujita Y., Kouda K., Yura A., Kadowaki E., Sato Y., Moon J. S., Tomioka K., Okamoto N., Kurumatani N., Serum undercarboxylated osteocalcin levels are inversely associated with glycemic status and insulin resistance in an elderly Japanese male population: fujiwara-kyo Osteoporosis Risk in Men (FORMEN) Study. Osteoporosis International 2012 23 2 761 770 2-s2.0-79952851894 10.1007/s00198-011-1600-7
14. Friedewald W. T., Levy R. I., Fredrickson D. S., Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry 1972 18 6 499 502 2-s2.0-0015348189
15. Grundy S. M., United States cholesterol guidelines 2001: expanded scope of intensive low-density lipoprotein-lowering therapy. American Journal of Cardiology 2001 88 7B 23J 27J 2-s2.0-0035845991 (Pubitemid 32938248)
16. Kanazawa I., Yamaguchi T., Tada Y., Yamauchi M., Yano S., Sugimoto T., Serum osteocalcin level is positively associated with insulin sensitivity and secretion in patients with type 2 diabetes. Bone 2011 48 4 720 725 2-s2.0-79952698270 10.1016/j.bone.2010.12.020
17. Pittas A. G., Harris S. S., Eliades M., Association between serum osteocalcin and markers of metabolic phenotype. Journal of Clinical Endocrinology & Metabolism 2009 94 3 827 832
18. Sniderman A. D., Non-HDL cholesterol versus apolipoprotein B in diabetic dyslipoproteinemia: alternatives and surrogates versus the real thing. Diabetes Care 2003 26 7 2207 2208 2-s2.0-2142771357
19. Walldius G., Jungner I., Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. Journal of Internal Medicine 2004 255 2 188 205 2-s2.0-1242340399 10.1046/j.1365-2796.2003.01276.x (Pubitemid 38241363)
20. Sierra-Johnson J., Somers V. K., Kuniyoshi F. H. S., Garza C. A., Isley W. L., Gami A. S., Lopez-Jimenez F., Comparison of apolipoprotein-B/ apolipoprotein-AI in subjects with versus without the metabolic syndrome. American Journal of Cardiology 2006 98 10 1369 1373 2-s2.0-33750498485 10.1016/j.amjcard.2006.06.029 (Pubitemid 44666643)
21. Walldius G., Jungner I., Holme I., Aastveit A. H., Kolar W., Steiner E., High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. The Lancet 2001 358 9298 2026 2033 2-s2.0-0035894648 10.1016/S0140-6736(01)07098-2 (Pubitemid 34084825)
22. Polgreen L. E., Jacobs D. R., Nathan B. M., Association of osteocalcin with obesity, insulin resistance, and cardiovascular risk factors in young adults. Obesity 2012 20 11 2194 2201
23. Yeap B. B., Chubb S. A., Flicker L., Associations of total osteocalcin with all-cause and cardiovascular mortality in older men. The Health In Men Study. Osteoporosis International 2012 23 2 599 606
24. Oosterwerff M. M., van Schoor N. M., Lips P., Osteocalcin as a predictor of the metabolic syndrome in older persons: a population-based study. Clinical Endocrinology 2013 78 2 242 247